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Figure 1
Perlecan DV is upregulated after stroke in 
rodents. (A) Anti-DV Western blot analy-
sis of post-stroke rat brain, with GAPDH 
internal loading control. DV levels were 
assessed in both ipsilateral (stroke) and 
contralateral hemispheres on the post-
stroke days as labeled. GAPDH load-
ing control lanes on contralateral PSD 
5 and 7 were run on the same gel but 
were noncontiguous. (B) Densitometry 
analysis of DV Western blot as shown 
in A. DV band density intensities were 
normalized to their respective GAPDH 
bands (**P < 0.01 between ipsi- and 
contralateral hemispheres for each PSD, 
n = 15 per PSD). (C) DV and CD31 co-
immunohistochemistry of rat stroke and 
corresponding contralateral brain tissue 
on PSD 3 and 7. Scale bar: 50 μM. (D) 
Anti-DV Western blot analysis of PSD 3 
brain tissue from WT littermate mice and 
Pln–/– mice, with GAPDH as internal load-
ing control. (E) Plot of mean ischemic 
lesion volumes of stroke WT mice and 
Pln–/– mice (**P < 0.01 between groups on 
each PSD, n = 15 per group per PSD). (F) 
WT or Pln–/– mouse brain TTC staining at 
PSD 3. Yellow asterisks indicate ischemic 
lesions (TTC-negative, appears white).
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Perlecan DV is upregulated after stroke. Perlecan is rapidly processed 




















































































fied morphologically)  in  the  rat but was essentially absent  in 
Table 1
DV treatment does not alter vital signs, blood gases,  
or serum electrolytes
Measured physiologic  PBS-treated  DV-treated
parameters (mean ± SD) (mean ± SD)
Systolic blood pressure (mmHg) 114.1 ± 2.4 113.9 ± 3.0
Heart rate (bpm) 300 ± 27.75 299.71 ± 27.17
Breathe rate (BrPM) 105.58 ± 12.85 108.62 ± 13.83
Partial pressure O2 (mmHg) 165.1 ± 35.5 171.1 ± 16.1
Partial pressure CO2 (mmHg) 54.9 ± 10.9 51.1 ± 1.4
Hematocrit (%) 34.7 ± 3.9 33.2 ± 6.5
Sodium (mEq/l) 150.3 ± 3.3 152.8 ± 1.5
Potassium (mEq/l) 6.4 ± 0.9 6.4 ± 0.8
Ionized calcium (mg/dl) 5.2 ± 0.3 5.2 ± 0.04
Oxygen saturation % 98.6 ± 0.8 98.8 ± 0.4
pH 7.3 ± 0.02 7.3 ± 0.1
Measurements of mice (n = 10 per treatment group) taken on PSD 1, 
two hours after i.p. injection of PBS (baseline) or DV (total of 26 hours 
after stroke). No significant differences in any of these parameters was 
noted between PBS and DV treatment. BrPM, breaths per minute.
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Administered DV reaches stroke brain tissue. (A) PSD 5 rat brain immunostained for 
administered DV (anti-HIS antibody, red) and DAPI nuclear stain (blue). Scale bar: 
1 mm. (B) Von Willebrand factor (green) and HIS (red) co-immunohistochemistry of 
stroke, peri-infarct, and contralateral brain tissue as labeled. Scale bar: 10 μm. (C) 
Higher-magnification images of von Willebrand factor, DV (anti-His), and DAPI co-
immunohistochemistry of stroke and peri-infarct brain tissue (as in B). Scale bar: 10 
μm. (D) DV (detects both endogenous and administered DV) and HIS (detects only 
administered DV) Western blot analysis of stroke ipsilateral (I) brain tissue or cor-
responding contralateral (C) non-stroke tissue from PBS- or DV-treated animals. (E) 
X-ray and IR-800 image overlay (with corresponding signal intensity color spectrum 
scale) of stroke mice treated with IR-800–labeled DV or IR-800 control. L, left.
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Figure 3
DV is neuroprotective. (A and B) Mean ischemic lesion volumes mea-
sured from brain sections stained with TTC (PSD 1–3) or H&E (PSD 
7 and 15) in WT mice treated with different doses of DV (A) or in WT 
and Pln–/– mice treated as indicated (B) (*P < 0.05, **P < 0.01, n = 15 
per treatment group per PSD). (C) WT or Pln–/– mouse brain TTC stain-
ing at PSD 3, or WT H&E staining on PSD 15, after animals received 
i.p. PBS or DV injections (1 mg/kg). Yellow asterisks and red circles 
indicate ischemic lesions. (D) Cresyl violet, cleaved caspase-3, and 
TUNEL staining, with propidium iodide (PI) nuclear counterstain, in the 
peri-infarct area in WT mice treated with PBS or with DV. Scale bars: 
5 μm (cresyl violet) and 10 μm (caspase-3 and TUNEL). 
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DV restores post-stroke motor function. (A) Cylinder test of post-stroke motor function in stroke rats treated as labeled (**P < 0.01, all treatment 
groups compared with PBS control, P = NS between all treatment groups; n = 15 per treatment group). (B) Vibrissae-elicited forelimb placement 
test on stroke littermate WT or Pln–/– mice treated as labeled. DV-treated (0.5 mg/kg and 1 mg/kg) groups were significantly different from their 
untreated counterparts (**P < 0.01). The DV-treated (0.5 mg/kg) WT mice were significantly different from the DV-treated (1 mg/kg) WT mice 
(P < 0.05). The Pln–/– DV-treated mice were significantly different from the WT DV-treated mice (*P < 0.05). The WT 1 mg/kg DV group was 
indistinguishable from the sham surgery control group (P = NS).
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DV neuroprotection is VEGF and VEGFR mediated. (A) Anti-VEGF Western blot analysis of ipsilateral stroke hemispheres as labeled, with 
GAPDH as internal loading control. (B) Densitometry analysis of VEGF Western blot as shown in A as normalized to corresponding GAPDH 
bands (**P < 0.01, n = 15 per treatment group, per PSD). (C) Plot of VEGF ELISA ipsilateral stroke brain tissue treated as labeled (#P < 0.01 as 
compared with corresponding PBS-treated WT control or as labeled, n = 3 per treatment group per PSD). (D) Mean ischemic lesion volumes 
of stroke WT mice on PSD 1–3 treated as labeled (**P < 0.01, n = 15 per treatment group per PSD). (E) Vibrissae-elicited forelimb place-
ment test on WT mice treated as labeled. DV had no effect in animals also treated with PTK787/ZK 222584 (P = NS). (F) NeuN and VEGFR2 
co-immunohistochemistry of PSD 5 peri-infarct brain tissue of mice treated as labeled. White arrows indicate cells that were positive for 
both NeuN and VEGFR2. Scale bar: 50 μm. (G) Number of NeuN- and VEGFR2-positive cells per mm2 in the peri-infarct regions as labeled 
(**P < 0.01, n = 10 images per animal, 5 animals per treatment condition).
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DV does not increase post-stroke blood-brain barrier permeability. (A) Schematic of EB-labeled albumin extravasation after stroke in vivo blood-
brain permeability paradigm, wherein mice were subjected to stroke and treated with PBS or DV 2, 8, or 24 hours after stroke, followed by i.v. 
injection of albumin-mixed EB dye (4 hours later), and sacrificed 4 hours later. Alternatively, mice were treated 24 hours after stroke and then 
every other day with DV or PBS until PSD 14, followed by i.v. injection of albumin-mixed EB dye, and sacrificed 4 hours later. (B) Images of 
brains from mice treated with PBS or DV, per the schematic in A, showing the brain surface spread of EB-labeled albumin as circled in black 
and indicated by the black arrow in each image. (C) EB-labeled albumin extravasation volume for the conditions and times of treatment as in B 
(n = 5 per treatment group, per post-stroke time). (D) Plot of total EB-labeled albumin (μg) extravasated per mg of brain tissue.
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suggest  that  DV  indirectly 
protects neurons via enhance-
ment  of  VEGF  release  from 
endothelial  cells,  rather  than 
via direct effects on neurons.
DV unexpectedly enhances 
brain angiogenesis in a VEGF- 
and VEGFR-dependent fashion. 
Although DV is a known inhib-





possibility  that DV  could  be 






































DV is neuroprotective in vitro via enhancement of VEGF secretion from brain endothelial cells. (A) VEGF 
ELISA from conditioned media of mouse brain endothelial cells with different treatment concentrations of DV 
over time as indicated (*P < 0.05, **P < 0.01, n = 15 per treatment group per time measured). (B) Schematic 
of fetal cortical neuron OGD protocol used in this study. In B–D: pink, neuron medium (Medium); orange, 
conditioned medium (CM). (C) VEGF ELISA data from fresh neuron medium and CM with or without DV 
(**P < 0.01, n = 5 separate experiments, each condition performed in triplicate per experiment). (D) Mean 
Alamar blue fluorescence measurements (excitation wavelength of 560 nm and emission wavelength of 
590 nm) of fetal cortical neurons exposed to OGD as outlined in B as an indicator of cell viability (**P < 0.01 
compared with CM alone, ##P < 0.01 compared with CM + DV, n = 5 separate experiments, each condition 
performed in triplicate per experiment).
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DV increases brain angiogenesis in a VEGF- and VEGFR-dependent 
fashion. (A) Von Willebrand factor immunohistochemistry (green) 
micrographs of peri-infarct brain on PSD 5 from mice treated as 
labeled. Scale bar: 10 μm. (B) Number of blood vessels/mm2 (as in A) 
in the peri-infarct region for each treatment group as labeled (*P < 0.05, 
#P < 0.01 compared with PBS-treated WT, n = 10 images per ani-
mal, 5 animals per treatment condition). (C) Ki-67 (green) and CD31 
(red) co-immunohistochemistry micrographs of peri-infarct brain of 
WT mice as labeled. Scale bar: 10 μm. (D) Number of Ki-67–positive 
blood vessels (CD31+) in the peri-infarct region of WT mice as labeled 
(**P < 0.01 compared with PBS-treated WT, n = 10 images per ani-
mal, 5 animals per treatment condition). (E) Matrigel capillary tube–like 
structure assay with mouse primary brain endothelial cells treated as 
labeled. Scale bar: 10 μm. (F) Quantification of Matrigel capillary tube 
assays (as in E) (**P < 0.01, n = 15 HPFs per experiment, 5 separate 
experiments, each condition in triplicate per experiment). (G) Prolifera-
tion of mouse dermal and brain endothelial cells as labeled after 48 
hours in serum-free medium as measured via MTS assay (**P < 0.01, 
n = 5 separate experiments, each condition performed in triplicate per 
experiment). Values shown as percent of control proliferation arbitrarily 
set at 100% for each cell type.
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Figure 9
DV effects are mediated via the α5β1 integrin in vivo. (A) Anti-α5β1 Western blot analysis from PSD 3 mouse brain tissue treated as labeled, 
with GAPDH as internal control. (B) α5β1 immunohistochemistry of mouse PSD 3 peri-infarct brain tissue with or without DV treatment. 
Scale bar: 10 μm. (C) Quantification of mean ischemic lesion volumes of stroke WT mice on PSD 1–3 as labeled (*P < 0.05, n = 15 per treat-
ment condition per PSD). (D) Cresyl violet staining, caspase-3 17- to 20-kDa cleavage product immunostaining, and TUNEL staining with 
PI of peri-infarct brain regions as labeled. Scale bars: 10 μm. (E) Vibrissae-elicited forelimb placement test on WT mice treated as labeled 
(n = 15 mice per condition from 3 separate experiments with 5 mice each). (F) Von Willebrand factor immunohistochemistry (green) on PSD 5 
from WT mice treated as labeled. Scale bar: 10 μm. (G) Peri-infarct blood vessel quantification as labeled (*P < 0.05, **P < 0.01 compared 
with PBS + IgG on the same day, n = 20 images analyzed per animal, 10 animals per experimental condition). (H) Anti-VEGF Western blot 
analysis of mouse stroke hemispheres with internal GAPDH as control. (I) Optical density quantification of VEGF Western blot analysis as 
shown in H (**P < 0.01, n = 5 per experimental condition).
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DV’s effects are mediated via the α5β1 integrin in vitro. (A) Mean percentage of brain endothelial cells (±SD) migrating toward 3% FBS (control) or 
DV with or without α5β1-GST soluble protein or α5 knockdown with α5 siRNA (as normalized to no chemoattractant negative control) (*P < 0.05, 
**P < 0.01, n = 5 separate experiments, each condition performed in triplicate per experiment) (B) Brain endothelial cells, either untreated or 
treated with DV or DV plus the α5β1-specific binding peptide CRRETAWAC, on Matrigel after 12 hours. Scale bar: 10 μm (C) Quantification 
of proliferation of brain endothelial cells ± α5 integrin plasmid after 48 hours ± DV measured via MTS assay (n = 15, mean ± SD normalized to 
control proliferation arbitrarily set to 100%, **P < 0.01, n = 5 separate experiments, each condition performed in triplicate per experiment). (D) 
Optical biosensor traces showing the association and dissociation of DV and BSA (control) with immobilized α5β1integrin at the concentrations 
(in M) listed; RU, relative units. (E) VEGF ELISA data from brain endothelial cell–secreted medium treated as labeled (**P < 0.01. n = 5 sepa-
rate experiments, each condition performed in triplicate per experiment). (F) Schematic for DV-induced VEGF production and release in brain 
microvascular endothelial cells via α5β1 integrin. Inhibitors used in this study are indicated with red lines. The various proposed effects of VEGF 
(i.e., stimulation of angiogenesis and neuroprotection) are also schematically illustrated.
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KA.  Larger  anastomoses  in  angiotensinogen-
knockout mice attenuate metabolic disturbances 
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